Bioventus vs Orthofix Medical
BVS and OFIX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BVS and OFIX compare
Bioventus is the larger company, worth 3.2 times as much as Orthofix Medical ($924M against $292M).
Bioventus grew revenue faster over the last twelve months (3.9% versus 2.1% for Orthofix Medical).
Bioventus keeps more of each dollar of sales as profit, with a net margin of 9.8% compared with −5.4% at Orthofix Medical.
Bioventus scores higher on the StockData Score (14 against 10 for Orthofix Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BVS | OFIX |
|---|---|---|
| Size and price | ||
| Market cap | $924M | $292M |
| Share price | $10.99 | $7.18 |
| Change, 1 year | 46.7% | −52.2% |
| Change, 5 years | −21.6% | −76.9% |
| Beta (5Y) | 0.91 | 1.10 |
| Employees | 930 | 1,605 |
| StockData Score | ||
| Total score | 14 (better) | 10 |
| Valuation score | 4 | 4 |
| Growth score | 3 (better) | 2 |
| Performance score | 5 (better) | 3 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 13.7× | – |
| P/S | 1.6× | 0.4× (better) |
| P/B | 3.8× | 0.7× (better) |
| EV/EBITDA | 14.4× | 13.2× (better) |
| P/FCF | 10.9× | – |
| FCF yield | 9.2% (better) | −15.2% |
| Fair value | $16.36 | $14.01 |
| Margin of safety | 32.8% | 48.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 3.9% (better) | 2.1% |
| Revenue growth, 5Y average | 12.1% | 15.1% (better) |
| Net income growth (TTM) | 655% | – |
| EPS growth (TTM) | 627% | – |
| Profitability | ||
| Gross margin | 68.7% | 70.9% (better) |
| Operating margin | 9.7% (better) | −2.5% |
| Net margin | 9.8% (better) | −5.4% |
| FCF margin | 14.5% (better) | −5.3% |
| Return on equity | 28.2% (better) | −10.3% |
| Return on invested capital | 12.8% (better) | −2.9% |
| Financial health | ||
| Debt / equity | 0.96 | 0.52 (better) |
| Net debt / EBITDA | 2.44 (better) | 4.17 |
| Current ratio | 1.68 | 3.11 (better) |
| Altman Z-score | 2.19 (better) | 1.05 |
| Piotroski F-score | 8 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | −0.31% | – |
| Shareholder yield | −0.31% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 71.2% | 94.0% |
| Held by insiders | 29.0% | 25.1% |
| Insider net buying, 12 months | −$181K | $218K (better) |
| Short interest, % of float | 5.1% | 7.1% |
Go deeper
- BVS stock overview
- BVS income statement
- BVS valuation and score
- OFIX stock overview
- OFIX income statement
- OFIX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.